Nanoparticle-based IV formulation
Pre-clinical- Indications
- Radiation therapy side effects
Company intelligence / Profile preview
BioCurity has conducted extensive preclinical studies in models of head and neck, lung, breast, pancreatic, prostate, and colorectal cancer showing that cerium oxide nanoparticles are regenerative and not consumed in the reaction. Their formulations have shown positive results in preventing radiation damage to normal tissues without impacting the effectiveness of radiation treatment on cancerous tissues.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BioCurity Pharmaceuticals Inc..